论文部分内容阅读
各种原因导致的关节软骨（articular cartilage, AC）损伤的治疗至今仍是临床一大难题；而软骨组织工程技术的出现为AC损伤治疗带来了新的希望。软骨组织工程技术可分为两类，即基于细胞的组织工程技术和无细胞的组织工程技术。虽然基于细胞的组织工程技术可以在一定程度上修复软骨损伤，但仍然具有细胞来源受限、成本高、疾病传播风险和操作程序复杂等缺陷；而无细胞的组织工程技术避免了这些缺点，为原位AC再生带来了希望。无细胞的组织工程技术主要是通过募集内源性干细胞/祖细胞（stem cells/progenitor cells, SCPCs）到达软骨损伤部位，并提供合适的再生微环境促进细胞的增殖和成软骨分化，进一步促进新生软骨组织成熟，因此也被称为细胞归巢的原位组织工程技术。成功地募集内源性SCPCs是原位软骨组织工程中的第一步。选择合适的趋化剂来实现内源性SCPCs的募集尤为重要。因此，通过简要介绍软骨损伤后趋化反应，系统综述传统趋化剂（如趋化因子、生长因子等）和新兴趋化剂（如功能性多肽、外泌体和核酸适配体等），评估趋化剂与递送装置之间的结合方式，讨论趋化剂介导的原位组织工程技术的前景与挑战，为基于内源性SCPCs归巢的原位组织工程技术的设计提供理论基础。“,”The treatment of articular cartilage (AC) injury caused by various reasons is still a major clinical problem. The emergence of cartilage tissue engineering brings new hope for the treatment of AC injury. In general, AC tissue engineering can be divided into two categories, including cell-based tissue engineering and cell-free tissue engineering. Although cell-based tissue engineering can repair cartilage damage to a certain extent, existing therapeutic strategies still suffer from limited cell sources, high costs, risk of disease transmission, and complex procedures. However, the cell-free tissue engineering avoids these shortcomings and brings hope for in-situ AC regeneration. Non-cellular tissue engineering is mainly used to recruit endogenous stem cells/progenitor cells (SCPCs) to reach the site of cartilage injury, and provide a suitable regenerative microenvironment to promote cell proliferation and chondrogenic differentiation, then the maturation of new cartilage tissue was promoted. Therefore, it is also called as cell-homing in situ tissue engineering. Successful recruitment of endogenous SCPCs is the first step in in-situ cartilage tissue engineering. This review aims to introduce chemokine response of cartilage injury, systematically summarize traditional chemoattractant (chemokines and growth factors etc.) and emerging chemoattractant (functional peptides, exosomes and nucleic acid adapters etc.), evaluate the combination mode between chemoattractant and delivery devices, discuss the prospects and challenges of chemoattractant-mediated in situ tissue engineering and provide theoretical basis for the design of endogenous SCPCs homing-based in situ tissue engineering.